FDA approves Cystaran for rare eye disease

FDA approved Cystaran cysteamine ophthalmic solution from Sigma-Tau Group (Pomezia, Italy) to treat corneal cystine crystal accumulation in patients with cystinosis, a rare genetic lysosomal storage d...